Navigation Links
Barrow scientist leads insula research
Date:7/7/2010

(PHOENIX, AZ) -- A scientist at Barrow Neurological Institute is leading the global discussion and research on a hidden lobe of the brain called the insula. A.D. "Bud" Craig, PhD, who began studying the often-ignored lobe more than two decades ago, has organized and edited a special edition of the journal Brain Structure and Function dedicated to the emerging medical and scientific interest in the insula.

This special edition contains 21 articles describing the latest research and insights from scientists and clinicians from around the world who recognize the insula as the key to their own field of interest and perhaps human consciousness.

The insula is a prune-sized area located deep within the brain. It was long ignored because scientists could not probe the area with surface electrodes. With the invention of sophisticated brain imaging techniques such as functional magnetic resonance imaging (fMRI) activation of the region has been observed in a surprisingly wide range of studies.

"Rapidly accumulating evidence indicates that this area of the brain is uniquely involved in virtually every human emotion and behavior," says Dr. Craig. "Similarly, clinical evidence indicates that it is crucially involved in a variety of syndromes, including addiction, anxiety, depression, anosognosia, schizophrenia and frontotemporal dementia."

Dr. Craig says that the overall goal of the special issue on the insula in Brain Structure and Function is to provide a solid starting point for new investigators by identifying the issues and opportunities for advances in the knowledge of this unique portion of the human brain.

An "intense" discussion about the role of the insula is urgently needed, says Dr. Craig, because many researchers have not had knowledge of its role and so little had been written about it.

"The insula is finally emerging from its hiding place inside the human brain," says Dr. Craig. "Its central importance to all human feelings and behaviors makes it an extraordinarily important target for potential treatments of many mental dysfunctions, using drugs or sophisticated biofeedback methods."


'/>"/>

Contact: Lynne Reaves
lynne.reaves@chw.edu
602-406-4734
St. Joseph's Hospital and Medical Center
Source:Eurekalert

Related biology news :

1. Barrow scientist receives $450K MDA grant
2. New era of pain drugs advanced by Barrow researcher
3. Barrow researcher finds natural hydrogel helps heal spinal cord
4. Barrow scientist awarded $400,000 grant to study cell associated with intuition and autism
5. Barrow scientists solve 200-year-old scientific debate involving visual illusions
6. Marine scientists return with rare creatures from the deep
7. Scientists find direct line from development to growth
8. UM School of Medicine scientists develop new strategy that may improve cognition
9. Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria
10. NOAA-supported scientists predict larger than average Gulf dead zone
11. SAGE to publish the Bulletin of the Atomic Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: